Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 11/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3798190 | 0.86 | CES2 (0.59) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL9549256 | 0.86 | KMT2A (0.53) | L3MBTL1GAAMAPTLMNANPSR1 | |
| SCHEMBL7186388 | 0.85 | L3MBTL1 (0.62) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL8123793 | 0.84 | CA1 (0.61) | POLBRAB9AHTTSMN1; SMN2 | |
| SCHEMBL155030 | 0.84 | CA1 (0.61) | POLBRAB9AHTTSMN1; SMN2 | |
| SCHEMBL15385195 | 0.82 | PARP10 (0.67) | MAOBALDH1A1 | |
| SCHEMBL2778728 | 0.82 | MAPT (0.47) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL933535 | 0.82 | L3MBTL1 (0.75) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL18319674 | 0.82 | MAPT (0.47) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL6658281 | 0.82 | MAPT (0.72) | L3MBTL1GAAMAPTLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000476-B2 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-10000476-B2 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20160340349-A1 | PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| US-20160340349-A1 | PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| US-9447072-B2 | Pyridone derivative and pharmaceutical containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-9447072-B2 | Pyridone derivative and pharmaceutical containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20160168540-A1 | COMPOSITION FOR MAINTAINING PLATELET FUNCTION | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168540-A1 | COMPOSITION FOR MAINTAINING PLATELET FUNCTION | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| EP-3006029-A1 | COMPOSITION FOR MAINTAINING PLATELET FUNCTION | Kaken Pharmaceutical Co., Ltd. (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-2349999-B1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIV SAARLAND (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-20040254241-A1 | Enzyme inhibitor; cognition activators | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1431280-A1 | ARYL SULFAMATE DERIVATIVES | Kyowa Hakko Kogyo Co., Ltd (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-6603046-B1 | The invention is drawn to novel bis-aromatic a, beta -unsaturated ketones. The compounds are useful in the treatment and prophylaxis of diseases caused by parasites or bacteria. | LICA PHARMACEUTICALS A/S (DK) | 2003-08-05 | — | — | US | disclosed |
| US-6413995-B1 | IMMUNOMODULATORS | TSUMURA & CO. (JP) | 2002-07-02 | — | — | US | disclosed |
| EP-1142875-A1 | CINNAMAMIDE DERIVATIVES AND DRUG COMPOSITIONS CONTAINING THE SAME | TSUMURA & CO. (JP) | 2001-10-10 | — | — | EP | disclosed |
| EP-0634927-B1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES, OR BACTERIA | LICA PHARMACEUTICALS AS (DK) | 2001-07-04 | — | — | EP | disclosed |
| US-5985935-A | PARASITICIDES OR BACTERICIDES | STATENS SERUMINSTITUT (DK) | 1999-11-16 | — | — | US | disclosed |
| EP-0634927-A1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES, OR BACTERIA | STATENS SERUMINSTITUT (DK) | 1995-01-25 | — | — | EP | disclosed |
| WO-1994002145-A2 | 2-ARYL-4-QUINOLONES AS ANTITUMOR COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 1994-02-03 | — | — | WO | disclosed |
| WO-1993017671-A1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES, OR BACTERIA | STATENS SERUMINSTITUT (DK) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254241-A1 | Enzyme inhibitor; cognition activators | SULT1A1, STS, CYP26A1 | L3MBTL1 1578/4885GAA 292/4885MAPT 3105/4885 |
| US-20160340349-A1 | PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | PLPBP, PDXK, PNPO | L3MBTL1 4866/4885GAA 2974/4885MAPT 2709/4885 |
| US-10000476-B2 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | PNPO, PDXK, PLPBP | L3MBTL1 4864/4885GAA 2602/4885MAPT 3357/4885 |
| US-20160168540-A1 | COMPOSITION FOR MAINTAINING PLATELET FUNCTION | PF4, F2, PFKP | L3MBTL1 4770/4885GAA 4821/4885MAPT 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.